Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
Context Tucatinib (CYP2C8 substrate) and quercetin (CYP2C8 inhibitor) are two common drugs for the treatment of cancer. However, the effect of quercetin on the metabolism of tucatinib remains unknown.Objective We validated a sensitive method to quantify tucatinib levels in rat plasma based on ultra-...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2022.2048862 |
| _version_ | 1819009061034655744 |
|---|---|
| author | Ying Zhang Ya-nan Liu Saili Xie Xuegu Xu Ren-ai Xu |
| author_facet | Ying Zhang Ya-nan Liu Saili Xie Xuegu Xu Ren-ai Xu |
| author_sort | Ying Zhang |
| collection | DOAJ |
| description | Context Tucatinib (CYP2C8 substrate) and quercetin (CYP2C8 inhibitor) are two common drugs for the treatment of cancer. However, the effect of quercetin on the metabolism of tucatinib remains unknown.Objective We validated a sensitive method to quantify tucatinib levels in rat plasma based on ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS), which was successfully employed to explore the effect of quercetin on tucatinib pharmacokinetics in rats.Materials and methods An Acquity UPLC BEH C18 column was applied to achieve the separation of tucatinib and internal standard (IS) talazoparib after protein precipitation with acetonitrile. Then, we used this assay to investigate the effect of different doses of quercetin (25, 50 and 100 mg/kg) on the exposure of orally administered tucatinib (30 mg/kg) in 24 Sprague-Dawley (SD) rats, which were randomly divided into three quercetin pre-treated groups and one control group (n = 6).Results Our developed assay was verified in all aspects of bioanalytical method validation, involving lower limit of quantification (LLOQ), selectivity, accuracy and precision, calibration curve, extraction recovery, matrix effect and stability. After pre-treatment with 100 mg/kg quercetin, AUC0→t, AUC0→∞ and Cmax of tucatinib were remarkably increased by 75.4%, 75.8% and 59.1% (p < 0.05), respectively, while CLz/F was decreased significantly by 47.3% (p < 0.05) when compared with oral administration of 30 mg/kg tucatinib alone. This change is dose-dependent.Conclusions This study will help better understand the pharmacokinetic properties of tucatinib with concurrent use with quercetin, and more clinical verifications were inspired to confirm whether this interaction has clinical significance in humans. |
| first_indexed | 2024-12-21T00:50:22Z |
| format | Article |
| id | doaj.art-cdceea949067450aabe0c09477d73b8d |
| institution | Directory Open Access Journal |
| issn | 1388-0209 1744-5116 |
| language | English |
| last_indexed | 2024-12-21T00:50:22Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj.art-cdceea949067450aabe0c09477d73b8d2022-12-21T19:21:25ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162022-12-0160162162610.1080/13880209.2022.2048862Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assayYing Zhang0Ya-nan Liu1Saili Xie2Xuegu Xu3Ren-ai Xu4Department of Pharmacy, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaThe Eye Hospital of Wenzhou Medical University, Wenzhou, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaContext Tucatinib (CYP2C8 substrate) and quercetin (CYP2C8 inhibitor) are two common drugs for the treatment of cancer. However, the effect of quercetin on the metabolism of tucatinib remains unknown.Objective We validated a sensitive method to quantify tucatinib levels in rat plasma based on ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS), which was successfully employed to explore the effect of quercetin on tucatinib pharmacokinetics in rats.Materials and methods An Acquity UPLC BEH C18 column was applied to achieve the separation of tucatinib and internal standard (IS) talazoparib after protein precipitation with acetonitrile. Then, we used this assay to investigate the effect of different doses of quercetin (25, 50 and 100 mg/kg) on the exposure of orally administered tucatinib (30 mg/kg) in 24 Sprague-Dawley (SD) rats, which were randomly divided into three quercetin pre-treated groups and one control group (n = 6).Results Our developed assay was verified in all aspects of bioanalytical method validation, involving lower limit of quantification (LLOQ), selectivity, accuracy and precision, calibration curve, extraction recovery, matrix effect and stability. After pre-treatment with 100 mg/kg quercetin, AUC0→t, AUC0→∞ and Cmax of tucatinib were remarkably increased by 75.4%, 75.8% and 59.1% (p < 0.05), respectively, while CLz/F was decreased significantly by 47.3% (p < 0.05) when compared with oral administration of 30 mg/kg tucatinib alone. This change is dose-dependent.Conclusions This study will help better understand the pharmacokinetic properties of tucatinib with concurrent use with quercetin, and more clinical verifications were inspired to confirm whether this interaction has clinical significance in humans.https://www.tandfonline.com/doi/10.1080/13880209.2022.2048862Drug–drug interactioncancer treatmentHER2-positive breast cancer |
| spellingShingle | Ying Zhang Ya-nan Liu Saili Xie Xuegu Xu Ren-ai Xu Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay Pharmaceutical Biology Drug–drug interaction cancer treatment HER2-positive breast cancer |
| title | Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay |
| title_full | Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay |
| title_fullStr | Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay |
| title_full_unstemmed | Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay |
| title_short | Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay |
| title_sort | evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel uplc ms ms assay |
| topic | Drug–drug interaction cancer treatment HER2-positive breast cancer |
| url | https://www.tandfonline.com/doi/10.1080/13880209.2022.2048862 |
| work_keys_str_mv | AT yingzhang evaluationoftheinhibitoryeffectofquercetinonthepharmacokineticsoftucatinibinratsbyanoveluplcmsmsassay AT yananliu evaluationoftheinhibitoryeffectofquercetinonthepharmacokineticsoftucatinibinratsbyanoveluplcmsmsassay AT sailixie evaluationoftheinhibitoryeffectofquercetinonthepharmacokineticsoftucatinibinratsbyanoveluplcmsmsassay AT xueguxu evaluationoftheinhibitoryeffectofquercetinonthepharmacokineticsoftucatinibinratsbyanoveluplcmsmsassay AT renaixu evaluationoftheinhibitoryeffectofquercetinonthepharmacokineticsoftucatinibinratsbyanoveluplcmsmsassay |